Translational Neuroscience Optimization of GlyT1 Inhibitor (NCATS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01911676|
Recruitment Status : Active, not recruiting
First Posted : July 30, 2013
Last Update Posted : April 2, 2020
|Condition or disease||Intervention/treatment||Phase|
|Cognitive Impairments Associated With Schizophrenia||Drug: PF-03463275 Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||90 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Translational Neuroscience Optimization of GlyT1 Inhibitor|
|Study Start Date :||August 2013|
|Estimated Primary Completion Date :||June 2020|
|Estimated Study Completion Date :||June 2020|
Experimental: PF-03463275 Active Dose #1
Active dose between 40mg
Experimental: PF-03463275 Active Dose #2
Active dose between 60mg
Placebo Comparator: Placebo
Placebo- no active dose of PF-03463275.
- Effect of PF-03463275 on Specific Cognitive Domains [ Time Frame: Change from baseline in cognitive measures at approximately 5 weeks ]To test the efficacy of PF-03463275 on cognitive test performance specifically, with change in specific cognitive domains including verbal and visual learning and short-term/working memory examined as exploratory analyses.
- Alteration in symptom domain scores and event related potentials (ERPs) with PF-03463275 [ Time Frame: Change from Baseline at approximately 1 week ]To determine whether PF-03463275 impacts symptom domain scores and visual event related potentials (ERPs), analogous to long-term potentiation (LTP) with PF-03463275 treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01911676
|United States, Connecticut|
|Connecticut Mental Health Center|
|New Haven, Connecticut, United States, 06519|
|VA Connecticut Healthcare System|
|West Haven, Connecticut, United States, 06516|
|Principal Investigator:||Deepak C D'Souza, MD||Yale University|